Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program.
cerebral palsy
cost-benefit analysis
magnesium sulphate
quality improvement
Journal
The Australian & New Zealand journal of obstetrics & gynaecology
ISSN: 1479-828X
Titre abrégé: Aust N Z J Obstet Gynaecol
Pays: Australia
ID NLM: 0001027
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
11
10
2021
received:
29
06
2021
accepted:
31
10
2021
pubmed:
30
11
2021
medline:
16
3
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
Substances chimiques
Neuroprotective Agents
0
Magnesium Sulfate
7487-88-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-171Informations de copyright
© 2021 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Références
Australian cerebral palsy register 2020 bulletin: rates and trends for prenatally and perinatally acquired cerebral palsy, birth years 1995-2014. Sydney, 2020. Available from: https://cpregister.com/wp-content/uploads/2020/10/ACPR-Report-2020-Bulletin_s_lr.pdf
Doyle LW, Crowther CA, Middleton P et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; 21: CD004661.
Cahill AG, Odibo AO, Stout MJ et al. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis. Am J Obstet Gynecol 2011; 205(542): e1-e7.
Bickford CD, Magee LA, Mitton C et al. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res 2013; 13: 527.
Crowther CA, Middleton PF, Voysey M et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med. 2017; 14: e1002398.
Chow SSW, Crighton P, Chambers GM, Lui K. Report of the Australian and New Zealand Neonatal Network (ANZNN) 2017. Sydney: ANZNN, 2019.
Burhouse A, Lea C, Ray S et al. Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection. BMJ Open Quality 2017; 6: e000189.
De Silva DA, Synnes AR, von Dadelszen P et al. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP) - implementation of a national guideline in Canada. Implement Sci 2018; 13: 8.
Doyle LW, Spittle AJ, Olsen JE et al. Translating antenatal magnesium sulphate neuroprotection for infants born <28 weeks' gestation into practice: a geographical cohort study. ANZJOG 2021; 61: 513-518.
Keir ASE, McIntyre S, Rumbold A et al. Antenatal magnesium sulphate to prevent cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2021. https://doi.org/10.1136/archdischild-2021-321817. Online ahead of the print.
Li J, O'Donoghue C. A Methodological Survey of Dynamic Microsimulation Models in UNU-MERIT Working Papers Maastricht. The Netherlands: Economic and Social Research Institute on Innovation and Technology, UNU-MERIT, 2012.
Kruse M, Michelsen SI, Flachs EM et al. Lifetime costs of cerebral palsy. Dev Med Child Neurol 2009; 51: 622-628.
Deloitte Access Economics. The Cost of Cerebral Palsy in Australia in 2018. Canberra: Deloitte Access Economics, 2019.
Backhouse A, Ogunlayi F. Quality improvement into practice. BMJ 2020; 368: m865.
Siwicki K, Bain E, Bubner T et al. Nonreceipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-2013. Aust NZ J Obstet Gynaecol 2015; 55: 233-238.
Crowther CA, Middleton PF, Bain E et al. Working to improve survival and health for babies born very preterm: the WISH project protocol. BMC Pregnancy Childbirth 2013; 13: 239.
Gibson CS, Scott H, Hernandez J. Cerebral Palsy in South Australia 2019. Adelaide: Women’s and Children’s Health Network, 2020.
Gatman K, May R, Crowther C. Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand - Ongoing barriers and enablers. ANZJOG 2020; 60: 44-48.
Braithwaite J. Changing how we think about healthcare improvement. BMJ 2018; 361: k2014.
Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A Framework for Improvement. JAMA 1999; 282: 1458-1465.
Yeo KT, Thomas R, Chow SS et al. Improving incidence trends of severe intraventricular haemorrhages in preterm infants <32 weeks gestation: a cohort study. Arch Dis Child Fetal Neonatal Ed 2020; 105: 145-150.